Skip to contentO
Ovid Therapeutics Inc.
O
OVIDOvid Therapeutics Inc. Released May 8, 2018, after the close
10-Q filed May 8, 2018, 38 days after period end · 0001564590-18-011934
Q1 2018 · 10-Q
Revenue—
Net Income-$13.18M-$13.18MN/M vs Q1 2017N/M vs Q4 2017 EPS Diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
-$0.54-$0.54N/M vs Q1 2017N/M vs Q4 2017 Operating Income-$13,429,864N/M Operating Cash Flow-$12,926,412N/M Free Cash Flowderived-$12,933,993N/M ended Mar 31, 2018 · filed May 8, 2018 · 38 d after period end